Can Steroids Impair Immunotherapy for Cancer?
A new study suggests steroids could blunt the effects of some immunotherapies, but researchers say they remain necessary for some patients.
Progress Against Cancer
A new study suggests steroids could blunt the effects of some immunotherapies, but researchers say they remain necessary for some patients.
Researchers highlighted AI's potential to enhance clinical cancer care, including to improve diagnosis, guide precision medicine, and more.
Some women over 70 may not need chemotherapy for high-risk breast cancer, and an early trial finds a pancreatic cancer vaccine can trigger an immune response.
New clinical trials are exploring an array of CAR T-cell approaches for children with cancers of the brain and spinal cord.
Preliminary results found that combining relacorilant with nab-paclitaxel improved outcomes for women with advanced ovarian cancer.
The FDA has approved zongertinib for patients with unresectable or metastatic non-squamous non-small cell lung cancer that has HER2 tyrosine kinase domain mutations and has undergone prior treatment. The U.S. Food and Drug Administration...
The FDA has approved the first-in-class therapeutic dordaviprone for certain adult and pediatric patients with H3 K27M-mutated diffuse midline glioma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to dordaviprone (Modeyso)...
The AACR hosted a Virtual Patient Advocate Forum in July 2025 on technology’s role in cancer care.
Potential new approach to treating diffuse intrinsic pontine glioma uses engineered immune cells infused directly to the brain.
Most liver cancers can be prevented, and a common type of HPV is linked to skin cancer.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More